X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (55) 55
animals (46) 46
mice (35) 35
index medicus (30) 30
dimerization (18) 18
female (18) 18
biochemistry & molecular biology (16) 16
cell line, tumor (16) 16
mutation (15) 15
oncology (15) 15
biotechnology & applied microbiology (14) 14
protein kinase inhibitors - pharmacology (13) 13
proteins (13) 13
sirolimus - pharmacology (13) 13
cell line (12) 12
gene expression regulation - drug effects (12) 12
in-vivo (12) 12
medicine, research & experimental (12) 12
chronic myeloid-leukemia (11) 11
ligands (11) 11
mutations (11) 11
drug discovery (10) 10
genetics & heredity (10) 10
sirolimus - analogs & derivatives (10) 10
tacrolimus binding proteins (10) 10
xenograft model antitumor assays (10) 10
dose-response relationship, drug (9) 9
fusion proteins, bcr-abl - genetics (9) 9
genetic vectors (9) 9
imatinib (9) 9
male (9) 9
models, molecular (9) 9
molecular biology (9) 9
apoptosis - drug effects (8) 8
chemistry, medicinal (8) 8
dependovirus - genetics (8) 8
design (8) 8
expression (8) 8
fusion proteins, bcr-abl - antagonists & inhibitors (8) 8
genetics (8) 8
hematology (8) 8
immunophilins - metabolism (8) 8
molecular medicine (8) 8
pharmacology (8) 8
recombinant fusion proteins - metabolism (8) 8
resistance (8) 8
structure-activity relationship (8) 8
analysis (7) 7
antineoplastic agents - pharmacology (7) 7
article (7) 7
biological sciences (7) 7
cells (7) 7
chronic myelogenous leukemia (7) 7
genetic therapy - methods (7) 7
hematology, oncology and palliative medicine (7) 7
leukemia (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (7) 7
multidisciplinary sciences (7) 7
phosphotransferases (7) 7
pyrimidines - pharmacology (7) 7
rapamycin (7) 7
rats (7) 7
recombinant fusion proteins - genetics (7) 7
research (7) 7
signal-transduction (7) 7
sirolimus - administration & dosage (7) 7
transcriptional activation (7) 7
tumor cells, cultured (7) 7
activation (6) 6
binding sites (6) 6
cancer (6) 6
carrier proteins - metabolism (6) 6
cell proliferation - drug effects (6) 6
crystallography, x-ray (6) 6
erythropoietin - genetics (6) 6
gene expression regulation (6) 6
imidazoles - pharmacology (6) 6
immunophilins - genetics (6) 6
kinetics (6) 6
mice, nude (6) 6
mice, scid (6) 6
molecular sequence data (6) 6
protein engineering (6) 6
protein kinase inhibitors - chemistry (6) 6
proteins - metabolism (6) 6
pyridazines - pharmacology (6) 6
retroviridae - genetics (6) 6
therapy (6) 6
transduction, genetic (6) 6
antineoplastic agents - chemistry (5) 5
bacteriophages (5) 5
biochemistry (5) 5
cell biology (5) 5
complex (5) 5
crystal-structure (5) 5
dna-binding proteins - metabolism (5) 5
drug resistance, neoplasm - genetics (5) 5
fusion proteins, bcr-abl - metabolism (5) 5
gene-transfer (5) 5
genetic therapy (5) 5
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Gerstein Science - Stacks (1) 1
Robarts - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Research, ISSN 0008-5472, 04/2013, Volume 73, Issue 8 Supplement, pp. SY19-04 - SY19-04
Journal Article
2004, Practical approach series, ISBN 019963873X, Volume no. 266, 357
This new book is designed to enable researchers to design and undertake all aspects of a phage display project, from designing an experimental strategy and... 
Bacteriophages | Peptide Laboratory | Viral proteins | Microbial biotechnology | Bacterioplages
eBook
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | KINASE DOMAIN MUTATIONS | DIAGNOSED CHRONIC-PHASE | TYROSINE KINASE | INTERNATIONAL-WORKING-GROUP | FOLLOW-UP | CLINICAL RESISTANCE | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2012, Volume 30, Issue 1, pp. 78 - 84
Journal Article
2004, Practical approach series, ISBN 019963873X, Volume no. 266.
Web Resource
2004, Practical approach series, ISBN 019963873X, Volume no. 266
Web Resource
2004, ISBN 6610845298
Web Resource
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2016, Volume 22, Issue 22, pp. 5527 - 5538
Journal Article
Cancer Cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain... 
CHEMBIO | HUMDISEASE | CHRONIC MYELOGENOUS LEUKEMIA | DASATINIB BMS-354825 | MESYLATE | CML | ONCOLOGY | KINASE DOMAIN MUTATIONS | AMN107 | IMATINIB RESISTANCE | NILOTINIB | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Chronic myeloid leukemia | BCR protein | Imatinib | Mutagenesis | Abl protein | Mutation | Fusion protein | Tumors | Index Medicus | imatinib resistance | dasatinib | nilotinib | compound mutation
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2013, Volume 71, Issue 5, pp. 1315 - 1323
Journal Article
Experimental Biology and Medicine, ISSN 1535-3702, 12/2006, Volume 231, Issue 11, pp. 1685 - 1689
Research that bridges between scientific insights and clinical application is one of the most active and exciting areas of current biomedical activity. Much of... 
Industry | Academia | Oncology | Translational research | Interdisciplinary research | DRUG | MEDICINE, RESEARCH & EXPERIMENTAL | LUNG-CANCER | academia | industry | translational research | GENE-TRANSFER | MUTATIONS | interdisciplinary research | oncology | T-CELLS | Drug Industry - trends | Science - trends | Humans | Interprofessional Relations | Research - trends | Teaching
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2016, Volume 59, Issue 10, pp. 4948 - 4964
In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC),... 
CELL LUNG-CANCER | WILD-TYPE | CHEMISTRY, MEDICINAL | SRC TYROSINE KINASE | THERAPEUTIC TARGET | RESISTANCE | ATOMS-IN-MOLECULES | ALK INHIBITOR | IDENTIFICATION | ALK/ROS1 INHIBITOR | SMALL-MOLECULE INHIBITOR | Lung Neoplasms - drug therapy | Phosphines - pharmacology | Humans | Molecular Conformation | Lung Neoplasms - pathology | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Neoplasms, Experimental - pathology | Protein Kinase Inhibitors - chemistry | Phosphines - chemistry | Organophosphorus Compounds - pharmacology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Cell Survival - drug effects | Lung Neoplasms - enzymology | Administration, Oral | Pyrimidines - administration & dosage | Rats | Organophosphorus Compounds - chemistry | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Receptor Protein-Tyrosine Kinases - metabolism | Drug Discovery | Protein Kinase Inhibitors - administration & dosage | Animals | Receptor Protein-Tyrosine Kinases - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Organophosphorus Compounds - administration & dosage | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Neoplasms, Experimental - drug therapy | Drug Screening Assays, Antitumor
Journal Article
Chemical Biology & Drug Design, ISSN 1747-0277, 01/2011, Volume 77, Issue 1, pp. 1 - 11
The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia. However, drug resistance caused by kinase domain mutations has... 
kinase | ponatinib | AP24534 | drug discovery | X‐ray crystallography | structure‐based drug design | X-ray crystallography | Structure-based drug design | Drug discovery | Ponatinib | Kinase | structure-based drug design | C-ABL | CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BMS-354825 | DOMAIN MUTATIONS | CANCER | CHRONIC MYELOID-LEUKEMIA | STRATEGIES | THERAPY | IMATINIB | T315I MUTANT | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Piperazines - chemistry | Structure-Activity Relationship | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Pyrimidines - chemistry | Protein Kinase Inhibitors - chemistry | Protein Binding - drug effects | Imidazoles - chemical synthesis | Imidazoles - therapeutic use | Pyridazines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Imidazoles - pharmacology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Mutation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Benzamides | Fluoroimmunoassay | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Drug resistance | Analysis | Leukemia | STRUCTURE-ACTIVITY RELATIONSHIPS | MUTANTS | BASIC BIOLOGICAL SCIENCES | ENZYME INHIBITORS | TYROSINE | GENE MUTATIONS | PHOSPHOTRANSFERASES | MYELOID LEUKEMIA | MUTATIONS | ANTINEOPLASTIC DRUGS | 60 APPLIED LIFE SCIENCES | RESIDUES
Journal Article
Cancer Research, ISSN 0008-5472, 04/2013, Volume 73, Issue 8 Supplement, pp. 2084 - 2084
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 26, pp. 2693 - 2701
PurposeIn patients with crizotinib-treated, anaplastic lymphoma kinase gene (ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease... 
ALK | MULTICENTER | SOLID TUMORS | ONCOLOGY | CERITINIB | PHASE-1 TRIAL | CRIZOTINIB | OPEN-LABEL | WHOLE-BODY